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Predisposition to sporadic colorectal tumours is inﬂuenced by genes with minor phenotypic eﬀects. A case-control study was set
up on 295 patients treated for a large adenoma matched with polyp-free individuals on gender, age, and geographic origin in a 1 :
2 proportion. A second group of 302 patients treated for a small adenoma was also characterized to distinguish eﬀects on adenoma
occurrence and growth. We focussed the study on 38 single nucleotide polymorphisms (SNPs) encompassing 14 genes involved in
colorectalcarcinogenesis.EﬀectofSNPswastestedusingunconditionallogisticregression.Comparisonsweremadeforhaplotypes
within a given gene and for biologically relevant genes combinations using the combination test. The APC p.Glu1317Gly variant
appeared to inﬂuence the adenoma growth (P = .04, exact test) but not its occurrence. This result needs to be replicated and
genome-wide association studies may be necessary to fully identify low-penetrance alleles involved in early stages of colorectal
tumorigenesis.
Copyright © 2009 Sylviane Olschwang et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Colorectal cancer (CRC) is one of the most common human
malignancies in Western countries. The majority of the cases
develop from a premalignant lesion, the adenomatous polyp
[1]. Colorectal adenomas have high malignancy potential
when they are large in diameter and/or present with severe
dysplasia and/or a villous component [2]. Colonoscopic
polypectomy has been documented to signiﬁcantly reduce
the incidence of colorectal cancer [3, 4]. Therefore, the
identiﬁcation of factors associated with the development of
colorectal adenoma represents a major goal in colorectal
cancer prevention. They could indeed allow the selection of
individuals at risk of CRC who may beneﬁt from a screening
by colonoscopy.
The adenoma-carcinoma sequence suggests that col-
orectal adenomas and adenocarcinomas share common
environmental and genetic risk factors. An increased risk of
colorectal tumors has been found in relatives of patients with
large adenomas [5, 6]. A case-control study had suggested
that family history of colorectal cancer inﬂuenced only the
growth of adenomas or their malignant transformation [7].
However, relatively few epidemiologic studies explored
genetic risk factors in colorectal adenomas.2 Journal of Oncology
Table 1: Characteristics of the polymorphisms and minor allele frequencies (MAF) in polyp-free controls.
Gene Polymorphism Type MAF
TGFBR2
TGFBR2.1 Intronic; A/C (rs11924422) 0.38
TGFBR2.2 Intronic; C/G (rs12493607) 0.34
TGFBR2.3 Intronic; C/G (rs877572) 0.49
MLH1 MLH1.1 5 UTR; A/G (rs1800734) 0.21
MLH1.2 Genomic; C/T (rs6789043) 0.47
MSH2
MSH2.1 Intronic; A/G (rs3924917) 0.34
MSH2.2 Intronic; A/G (rs2347794) 0.36
MSH2.3 Intronic; G/T (rs3732182) 0.25
MSH2.4 Genomic; C/T (rs11125135) 0.22
MYH MYH.1 coding, missense; C/G (rs3219489) 0.25
MYH.2 Intronic; C/T (rs2185549) 0.25
TP53
P53.1 5 UTR; A/G (rs2909430) 0.11
P53.2 Coding, missense; C/G (rs1042522) 0.23
P53.3 Intronic; C/G (rs8064946) 0.11
AXIN2
AXIN2.1 3 UTR; A/T (rs7591) 0.40
AXIN2.2 Intronic; C/T (rs4074947) 0.24
AXIN2.3 Intronic; A/G (rs7224837) 0.10
AXIN2.4 Intronic; A/T (rs11655966) 0.24
AXIN2.5 Intronic; A/G (rs4128941) 0.04
AXIN2.6 Intronic; A/G (rs11079571) 0.21
AXIN2.7 Intronic; A/G (rs3923087) 0.27
AXIN2.8 Intronic; G/T (rs3923086) 0.49
AXIN2.9 coding, missense; A/G (rs2240308) 0.46
BAX
BAX.1 Intronic; C/T (rs1009316) 0.13
BAX.2 Intronic; A/G (rs1805419) 0.27
BAX.3 intronic; C/T (rs4645900) 0.05
CTNNB1 CTNNB1.1 promoter region; A/G (rs13075993) 0.41
CTNNB1.2 Intronic; A/G (rs4135385) 0.25
UGT1A1 UGT1A1 Genomic, microsatellite; delTA (rs8175347) 0.34
APC APC.1 Coding, missense; G/C (rs1801166) 0.01
APC.2 Coding, missense ; A/T (rs459552) 0.21
CARD15 CARD15.1 Coding, missense; G/C (rs2066845) 0.02
CARD15.2 Coding, insertion; ins C (rs5743293) 0.03
MDR1 MDR1.1 Coding, missense; G/T/A (rs2032582) 0.40, 0.02
MDR1.2 Coding, silent; C/T (rs1045642) 0.50
TS TS.1 3 UTR; delCTTTAA (rs16430) 0.31
TS.2 Promoter region; 28-bp VNTR (2R/3R) 0.48
HRAS1 HRAS1 Genomic, minisatellite; 28-bp VNTR 0.19
We investigated, through a case-control study, the rela-
tion between polymorphisms within a series of candidate
genes involved in colorectal tumorigenesis and putatively in
the formation and the development of colorectal adenomas
suchcarcinogenmetabolismenzymes,methylationenzymes,
DNA repair genes, oncogenes and tumor suppressor genes
[8].
2.MaterialsandMethods
2.1. Constitution of the Patients and Control Groups. The
GEnetics of ADEnomas (GEADE) study is a case-control
and family study of patients with high-risk adenomas
(≥10mm) [9]. The data were obtained from 18 participating
gastroenterology units of general hospitals in France. From
September 1995 to March 2000, 306 consecutive patients
with newly diagnosed colorectal large adenoma (LA) were
enrolled in the study. Patients with personal cancer history,
familial adenomatous polyposis, established hereditary non-
polyposis colorectal cancer or inﬂammatory bowel disease
were excluded. To distinguish genetic factors involved in
the occurrence of adenomas or in their growth, 307 cases
with small adenomas (with a diameter smaller than 0.5cm)
(SA) and 572 polyp-free controls (with normal colonoscopy)Journal of Oncology 3
(PF) were simultaneously enrolled in the same units. All
patients and controls were of Caucasian origin. Reason for
referral, family history of CRC, completeness of colonoscopy
were registered for all patients and controls. Two PF per
LA cases were selected as controls within over 2000 PF for
matching on age, gender, and geographic area. Patients with
SA were relatively rare and could not be matched with LA
cases.
Blood specimens were obtained at time of colonoscopy
and those patients who presented with a polyp were
included only when histological examination revealed the
adenomatous nature of the lesion. As polyps were totally
removed during colonoscopy, their natural evolution could
not be scored. After longitudinally section, half of the
tumor material was ﬁxed for histologic analysis and half was
frozen for molecular characterization. Twenty individuals
had to be excluded because of insuﬃcient tumor material:
11 patients with LA, 5 with SA, and 4 PF. The ﬁnal groups
contained 295 patients with LA, 302 with SA, and 568
PF as controls. Details of these groups have been reported
by Li` evre et al. [10]. All patients and controls signed an
informed consent after approval of the study by an ethic
committee for biomedical research (Le Kremlin-Bicˆ etre)
and the database was declared to the national committee
Commission Nationale de l’Informatique et des Libert´ es
(CNIL).
2 . 2 .G e n e sS t u d i e da n dG e n o t y p i n gP r o c e d u r e .Genes have
been selected for their role in colorectal tumorigenesis
and for the presence of frequent neutral polymorphisms.
The polymorphisms of MMP1, MMP3, and MMP7 gene
promoters, that are responsible for the degradation of
extracellular matrix components, had been previously stud-
ied and were not considered in the present analysis [10].
Three genes, TS, UGT1A1, and MDR1, are implicated in
folates, bilirubin metabolism, and transport of xenobiotic
respectively. All these pathways are suspected to play a role
in cancer occurrence or in the transformation of benign
lesions, folates by interfering with DNA synthesis and repair,
bilirubin by its known antioxydant properties, and transport
of xenobiotic by its detoxication function. Case-control
reports [8] exempliﬁed the relevance of these three genes
in addition to HRAS1. Three additional pathways have
been secondary studied including the WNT pathway (APC,
CTNNB1, AXIN2), the p53 pathway (TP53, BAX), the TGFB
pathway (TGFBR2), the main MMR and BER genes (MSH2,
MLH1, MYH), and CARD15 as part of the family with LRR
domains. All these genes have been strongly assessed for
their major role in oncogenesis, cycle cell control, apoptosis
regulation, cell adhesion and migration, proliferation, DNA
repair as their main functions.
Genotyping has been performed according to the nature
of the polymorphisms. Single nucleotide polymorphisms
(SNPs) have been characterized by Taqman analysis. The
VNTR of HRAS1 was studied by conventional electrophore-
sisafterPCRampliﬁcationon1.2%agarosegelsat2volts/cm
for 15–18 hours.
2.3. Statistical Analysis. Hardy-Weinberg proportions were
tested for each polymorphism. Linkage disequilibrium (LD)
between pairwise loci was estimated using the D  [11]
and r2 [12] measures. Association was ﬁrst tested for
each polymorphism separately. Genotype-speciﬁc odds ratio
(OR) and 95% conﬁdence intervals (CIs) were computed
usingunconditionallogisticregressionadjustedonmatching
factors; Wald test was used to assess the global eﬀect of
each polymorphism. The homozygous genotype for the
more frequent allele among controls was set as the reference
class. Homogeneity of allele frequencies within geographic
regions was previously checked. Tests of homogeneity and
unconditional logistic regression were done using the SAS
package software. The association was further examined
using the combination test, that allows the analysis of all
possible combinations of SNPs within a given gene or tightly
linked genes to test their association with the disease [13].
For each SNPs combination, the method computes a statistic
test contrasting the genotypic (or haplotypic) distribution
between cases and controls. Because all these tests are
correlated (many of them are nested in each other and
the SNPs are likely to be in LD), a permutation procedure
has been implemented which displays a signiﬁcance level
adequately adjusted for multiple testing. First, we used the
FAMHAP12 software to apply this method by performing
haplotypic tests [14]. Then the COMBINTEST (Jannot,
personal communication) was used to perform genotypic
tests. The method was extended to the test of combined
polymorphisms on diﬀerent genes that may act interac-
tively. To avoid multiple tests biases, we chose a three-step
strategy that minimizes the number of comparisons. First,
we considered two-by-two combinations of polymorphisms
chosen on their plausibility to interact with each other, for
instance, APC and MYH both responsible, when mutated,
for adenomatous polyposis. The second step consisted in
considering all combinations within a same pathway. Finally,
as a combination of polymorphisms may have an eﬀect
even if the genes are not suspected to interact with each
other and are not involved in the same pathway, all possible
combinations were considered if the ﬁrst two steps did not
reveal any signiﬁcant association. When several combina-
tions of polymorphisms were signiﬁcant within a given test,
it was possible to test nested combinations using Chi-square
calculation to determine whether a given polymorphism
adds a signiﬁcant contribution to the association found
[14].
3. Results
The average age was very similar in patients (62 years for
LA and 61 years for SA) and in PF controls (61 years). The
sex ratio (male/female) was quite similar in LA (1.7) and in
PF controls (1.5), slightly lower in SA (1.2) because of the
absence of matching.
Table 1 describes the characteristics of the polymor-
phisms studied and the allele frequencies in controls.
The distribution of genotypes in controls was consistent
with Hardy-Weinberg proportions for all polymorphisms4 Journal of Oncology
Table 2: Association analysis between single polymorphisms and colorectal adenomas: P-values.
Polymophism P-values for comparison∗
SA versus PF LA versus PF SA versus LA
∗∗
TGFBR2.1 0.81 0.46 0.25
TGFBR2.2 0.66 0.63 0.86
TGFBR2.3 0.91 0.94 0.92
MLH1.1 0.87 0.16 0.30
MLH1.2 0.69 0.75 0.68
MSH2.1 0.33 0.87 0.32
MSH2.2 0.57 0.93 0.57
MSH2.3 0.64 0.88 0.55
MSH2.4 0.71 0.85 0.80
MYH.1 0.82 0.71 0.56
P53.1 0.56 0.23 0.20
P53.2 0.40 0.16 0.78
P53.3 0.16 0.41 0.86
AXIN2.1 0.13 0.66 0.76
AXIN2.2 0.78 0.63 0.49
AXIN2.3 0.29 0.46 0.85
AXIN2.4 0.19 0.08 0.75
AXIN2.5 0.37 0.60 0.27
AXIN2.6 0.77 0.55 0.48
AXIN2.7 0.27 0.18 0.06
AXIN2.8 0.38 0.29 0.53
AXIN2.9 0.53 0.04 0.03
BAX.1 0.95 0.68 0.80
BAX.2 0.95 0.26 0.48
BAX.3 0.64 0.49 0.83
CTNNB1.1 0.58 0.64 0.85
CTNNB1.2 0.93 0.15 0.48
UGT1A1 0.05 0.29 0.76
APC.1 0.17
∗∗ 0.27
∗∗∗ 0.04∗∗∗
APC.2 0.80 0.26 0.38
CARD15.1 0.97 0.15 0.18
CARD15.2 0.48 0.57 0.97
MDR1.1 0.10 0.23 0.59
MDR1.2 0.69 0.04 0.09
TS.1 0.47 0.29 0.44
TS .2 0.41 0.25 0.87
HRAS1 0.38 0.17 0.65
∗P-value for the Wald test assessing the global eﬀect of SNP, uncorrected for multiple testing.
∗∗LA large adenoma, SA small adenoma, PF polyp-free.
∗∗∗Exact test.
except for TP53.3 (P = .0013 without correction for mul-
tiple testing). A similar departure from H-W proportions
(P = .010) was found in the HapMap European population
(http://www.ncbi.nlm.nih.gov/projects/SNP/) for this poly-
morphism.
All polymorphisms within a same gene were moderately
or not found in LD except MYH; MYH.1 and MYH.2 are
in quasicomplete disequilibrium (D  = 1a n d R2 = 0.99).
As these two polymorphisms appeared to be equivalent, we
analysed only MYH.1.
Analysis of single polymorphisms for the diﬀerent
comparisons, LA versus PF, LA versus SA, and SA versus
PF did not reveal any association for most of the genes
studied. Table 2 indicates the P-values obtained for each
polymorphism. The P-values found to be less than .05
were obtained for APC.1, MDR1.2, and AXIN2.9.T h e
corresponding OR and 95% conﬁdence intervals are given
in Table 3.
The results of the haplotypic and genotypic combination
testsperformedforeachgeneorgenecombinationareshownJournal of Oncology 5
Table 3: Association analysis between single polymorphisms and colorectal adenomas.
Polymorphism Genotype
∗ Odd ratio
∗∗
SA versus PF LA versus PF SA versus LA
TGFBR2.1 AC 0.91 [0.67−1.24] 1.06 [0.78−1.46] 1.22 [0.85−1.75]
CC 0.91 [0.58−1.41] 1.31 [0.85−2.02] 1.51 [0.91−2.51]
TGFBR2.2 GC 1.07 [0.79−1.44] 0.95 [0.69−1.28] 0.91 [0.64−1.29]
CC 1.23 [0.78−1.93] 1.18 [0.75−1.86] 0.91 [0.55−1.53]
TGFBR2.3 GC 0.93 [0.66−1.30] 1.00 [0.70−1.41] 1.08 [0.72−1.61]
CC 0.94 [0.63−1.41] 1.06 [0.70−1.59] 1.09 [0.68−1.74]
MLH1.1 AG 1.08 [0.79−1.46] 1.01 [0.74−1.38] 0.90 [0.63−1.29]
AA 1.11 [0.56−2.20] 1.80 [0.98−3.31] 1.64 [0.79−3.37]
MLH1.2 CT 1.04 [0.74−1.47] 1.14 [0.81−1.61] 1.08 [0.73−1.62]
C 1.18 [0.79−1.78] 1.08 [0.71−1.64] 0.90 [0.55−1.46]
MSH2.1 AG 0.97 [0.72−1.31] 0.93 [0.69−1.27] 0.94 [0.66−1.34]
GG 0.69 [0.43−1.13] 1.03 [0.65−1.62] 1.46 [0.83−2.54]
MSH2.2 AG 1.16 [0.86−1.57] 1.06 [0.78−1.44] 0.86 [0.60−1.23]
GG 0.98 [0.61−1.57] 1.02 [0.64−1.62] 1.10 [0.64−1.89]
MSH2.3 GT 0.88 [0.65−1.90] 0.99 [0.73−1.35] 1.11 [0.78−1.58]
GG 0.83 [0.45−1.53] 1.15 [0.65−2.04] 1.44 [0.72−2.85]
MSH2.4 CT 0.88 [0.65−1.20] 1.00 [0.74−1.37] 1.11 [0.77−1.58]
CC 1.00 [0.53−1.90] 0.82 [0.40−1.65] 0.88 [0.40−1.94]
MYH GC 1.05 [0.78−1.41] 0.89 [0.66-1.21] 0.85 [0.59−1.21]
CC 0.86 [0.46−1.59] 1.06 [0.59-1.89] 1.15 [0.57−2.33]
P53.1 AG 0.95 [0.65−1.38] 1.37 [0.96−1.95] 1.43 [0.95−2.18]
GG 0.50 [0.14−1.81] 1.01 [0.36−2.82] 1.62 [0.39−6.78]
P53.2 GC 1.17 [0.87-1.58] 1.34 [0.99−1-81] 1.11 [0.78-1.57]
CC 1.35 [0.78−2.36] 1.25 [0.69−2.25] 0.91 [0.48−1.75]
P53.3 GC 1.25 [0.87−1.78] 1.13 [0.78−1.63] 0.91 [0.60−1.37]
CC 0.40 [0.11−1.41] 0.53 [0.17−1.62] 1.28 [0.27−6.09]
AXIN2.1 AT 1.23 [0.89−1.69] 1.13 [0.82−1.56] 0.90 [0.62−1.31]
AA 1.51 [1.01−2.27] 1.18 [0.78−1.79] 0.84 [0.53−1.35]
AXIN2.2 TC 1.06 [0.78−1.42] 0.95 [0.71−1.29] 0.93 [0.66−1.31]
TT 1.23 [0.67−2.25] 0.72 [0.36−1.43] 0.64 [0.30−1.35]
AXIN2.3 AG 1.20 [0.84−1.71] 1.21 [0.84−1.73] 0.96 [0.64−1.44]
GG 2.26 [0.64−8.01] 1.71 [0.45−6.52] 0.68 [0.18−2.66]
AXIN2.4 AT 1.22 [0.90−1.65] 1.40 [1.03−1.89] 1.13 [0.79−1.59]
TT 1.51 [0.89−2.58] 1.35 [0.77−2.36] 0.95 [0.52−1.76]
AXIN2.5
∗∗∗ AG 1.26 [0.76−2.11] 0.86 [0.49−1.52] 0.70 [0.38−1.31]
AXIN2.6 AG 1.08 [0.79−1.46] 0.84 [0.62−1.15] 0.81 [0.57−1.16]
AA 1.23 [0.63−2.38] 0.99 [0.49−1.99] 0.82 [0.38−1.79]
AXIN2.7 AG 1.18 [0.88−1.59] 0.76 [0.56−1.04] 0.66 [0.47−0.94]
AA 1.48 [0.87−2.52] 1.07 [0.62−1.86] 0.74 [0.41−1.36]
AXIN2.8 GT 0.87 [0.62−1.23] 0.77 [0.55−1.08] 0.83 [0.56−1.24]
GG 1.11 [0.74−1.66] 0.91 [0.61−1.37] 0.78 [0.49−1.24]
AXIN2.9 AG 1.15 [0.83−1.60] 1.34 [0.95−1.91] 1.22 [0.82−1.82]
AA 0.96 [0.64−1.44] 1.67 [1.11−2.49] 1.86 [1.16−3.00]
BAX.1 TC 1.02 [0.73−1.42] 0.87 [0.61−1.22] 0.88 [0.59−1.29]
TT 1.19 [0.38−3.72] 1.16 [0.37−3.65] 1.02 [0.28−3.74]
BAX.2 AG 0.97 [0.72−1.30] 0.83 [0.61−1.12] 0.87 [0.61−1.23]
AA 1.05 [0.61−1.81] 1.23 [0.73−2.07] 1.24 [0.68−2.26]
BAX.3∗∗∗ TC 0.89 [0.55−1.45] 0.73 [0.43−1.23] 0.83 [0.46−1.52]
CTNNB1.1 AG 1.14 [0.83−1.56] 1.03 [0.75−1.42] 0.90 [0.62−1.31]
AA 1.23 [0.82−1.84] 1.21 [0.80−1.81] 0.93 [0.58−1.48]6 Journal of Oncology
Table 3: Continued.
Polymorphism Genotype
∗ Odd ratio
∗∗
SA versus PF LA versus PF SA versus LA
CTNNB1.2 AG 1.12 [0.61−2.06] 1.41 [0.71−2.79] 1.22 [0.56−2.66]
AA 1.13 [0.62−2.04] 1.73 [0.89−3.37] 1.44 [0.67−3.07]
UGT1A1 (TA)6/(TA)7 1.18 [0.86−1.62] 1.04 [0.76−1.41] 0.88 [0.62−1.26]
(TA)7/(TA)7 0.63 [0.38−1.05] 0.70 [0.43−1.14] 1.00 [0.56−1.81]
APC.1∗∗∗ GluGln 2.14 [0.67−7.00] 0.27 [0.01−2.11] 7.95 [1.05−354.36]
APC.2 AspVal 0.95 [0.70−1.28] 0.78 [0.57−1.05] 0.79 [0.56−1.14]
ValVal 1.20 [0.58−2.49] 0.94 [0.43−2.06] 0.73 [0.31−1.72]
CARD15.1
∗∗∗ GlyArg 1.01 [0.49−2.09] 0.51 [0.20−1.29] 0.50 [0.18−1.38]
CARD15.2
∗∗∗ Ins C 0.78 [0.39−1.56] 0.68 [0.33−1.39] 0.89 [0.38−2.09]
MDR1.1
GT 0.89 [0.63−1.25] 0.88 [0.63−1.22] 0.92 [0.63−1.36]
TT 1.32 [0.84−2.05] 1.15 [0.74−1.77] 0.91 [0.56−1.48]
AG 0.60 [0.22−1.64] 0.29 [0.08−1.03] 0.46 [0.11−1.99]
TA 2.86 [0.89−9.08] 1.27 [0.33−4.89] 0.41 [0.11−1.46]
MDR1.2 CT 1.00 [0.69−1.44] 0.76 [0.53−1.08] 0.69 [0.46−1.03]
TT 1.16 [0.76−1.79] 1.16 [0.78−1.74] 1.01 [0.63−1.61]
TS.1 2R/1R 0.99 [0.73−1.36] 1.25 [0.92−1.71] 1.24 [0.87−1.77]
1R/1R 1.35 [0.82−2.22] 1.33 [0.79−2.22] 0.99 [0.64−1.63]
TS.2 2R/3R 1.09 [0.75−1.59] 1.24 [0.85−1.82] 1.12 [0.72−1.75]
3R/3R 1.31 [0.86−1.98] 1.43 [0.94−2.16] 1.10 [0.68−1.78]
HRAS1 rare alleles 1.16 [0.83−1.61] 1.26 [0.91−1.75] 1.09 [0.75−1.59]
∗The genotype not shown is the reference one.
∗∗OR adjusted on age, sex, and group of centres; 95% CI is given into brackets.
∗∗∗Very few individuals with the homozygous genotype were observed.
in Table 4. When considering each gene separately, only APC
displayed a signiﬁcant diﬀerence between small and large
adenomas (P = .014 in haplotypic analysis and P = .07 in
genotypic analysis). As APC.1 alone and the combination
APC.1-APC.2 appeared both signiﬁcant, we tested whether
APC.2 provided a signiﬁcant contribution to the association,
which was not the case (χ2 = 2.12, 1df) showing that
the association was solely due to the APC.1 (p.Glu1317Gln)
polymorphism.Logisticregressionindicatedanoddsratioof
7.95(CI:1.05–354.3).ThecombinationAPC-MYH appeared
also signiﬁcant with a global P-value of .045. However,
the only signiﬁcant combination was APC.1-APC.2 already
found, showing that MYH does not provide any additional
contribution to the association between APC and adenomas.
No diﬀerence was found for the other two comparisons,
that is, SA versus PF and LA versus PF. Finally, the analysis
of all possible combinations did not provide any signiﬁcant
result.
4. Discussion
We investigated the role of candidate gene polymorphisms
in a case-control study of patients with large adenoma-
tous polyps (n = 295), compared to patients with small
adenomatous polyps (n = 302) and polyp-free controls
(n = 568). The 38 polymorphisms studied belonged to 14
genes possibly involved in increasing of colorectal cancer
risk [8]. The reason for comparing these diﬀerent groups
of patients was that diﬀerent genes might be involved in the
diﬀerent steps of carcinogenesis [7]. Using this case-control
study, we had shown that MMP polymorphism was most
probably involved in the occurrence, but not in the growth
of polyps [10]. Using the combination test, we had shown
that the eﬀect was due to a speciﬁc combination of MMP1-
MMP3 polymorphisms which was not found using logistic
regression. Indeed, a major property of this test is that it
allows the detection of polymorphisms with low marginal
eﬀects [13].
Multiple testing may be a limitation of studies in which
several polymorphisms in several genes are tested. The
combination test allows a correction for multiple tests on
tightly linked markers, which other methods of correction
such as Bonferroni, Benjamini-Hochberg, or FDR (false
discovery rate) do not. In the present study, we could show
thatthepositiveresultsobtainedforAXIN2 andMDR1when
analyzing single polymorphisms were false positives as these
results were not conﬁrmed when using the combination test.
For independent markers, there was no need for correcting
for multiple testing as our results were essentially negative.
Our study did not give evidence for an eﬀect of any of
the gene polymorphisms studied except the p.Glu1317Gly
variant of the APC gene. This variant was already described
in the previous studies with apparently conﬂicting results.
Some studies reported an eﬀect of this variant in patients
with multiple adenomas or colorectal cancer [15–17], andJournal of Oncology 7
Table 4: Eﬀect of combinations of gene polymorphisms in colorectal adenomas.
(a) P-values of combinations of polymorphisms withthin single genes.
Genes Haplotypic tests Genotypic tests
PA versus PF LA versus PF LA versus SA PA versus PF LA versus PF LA versus SA
TGFBR2 0.83 0.52 0.45 0.38 0.16 0.22
MLH1 0.64 0.41 0.63 0.45 0.24 0.13
MSH2 0.69 0.21 0.46 0.32 0.17 0.91
TP53 0.42 0.28 0.19 0.49 0.28 0.30
AXIN2 0.49 0.21 0.46 0.84 0.61 0.61
BAX 0.97 0.81 0.87 0.94 0.44 0.88
CTNNB1 0.43 0.16 0.37 0.79 0.43 0.76
MDR1 0.72 0.52 0.51 0.531 0.06 0.38
APC 0.16 0.26 0.014 0.19 0.45 0.08
CARD15 0.61 0.28 0.40 0.67 0.27 0.41
TS 0.63 0.21 0.75 0.60 0.43 0.59
(b) P-values of combinations of polymorphisms in diﬀerent genes.
Genes groups Haplotypic tests Genotypic tests
PA versus PF LA versus PF LA versus SA PA versus PF LA versus PF LA versus SA
APC-MYH 0.20 0.47 0.045 0.42 0.63 0.15
CNNB1-HRAS 0.47 0.25 0.58 0.74 0.31 0.58
MDR1-TP53 0.55 0.51 0.43 0.49 0.24 0.39
AXIN2-APC 0.36 0.19 0.07 0.19 0.73 0.40
TP53-BAX-
TGFBR2-APC 0.19 0.42 0.26 0.64 0.52 0.67
TS-MLH1-
MSH2-MYH 0.97 0.38 0.83 0.68 0.17 0.82
some others found an eﬀe c ti na d e n o m a sb u tn o ti nc a n c e r
[18, 19]. More recently, Hahnloser et al. [20]r e p o r t e da n
eﬀect of this variant in a group of patients with a small
number of adenomas (1 to 3 lifetime adenomas) and in
a group of CRC cases. None of these studies considered
the size of adenomas and could diﬀerentiate adenomas
at high-risk from those at low-risk of cancer. Our results
favour the hypothesis that the p.Glu1317Gly variant would
inﬂuence the growth and not the occurrence of adenomas,
and would have thus indirectly an inﬂuence on colorectal
cancer risk. Nevertheless, although the three groups are
paired on gender and geographic origin, it is not stated if
other known risk factors would inﬂuence adenoma growth.
It is thus important to plan a speciﬁc multivariate analysis
when building a replication sample.
Regarding the TS polymorphisms, we did not conﬁrm
the eﬀect of TS suggested in some studies. Chen et al. [21]
found a signiﬁcant eﬀect of the 3R allele of TS.2, particularly
of the 3R/3R genotype (OR = 3.3). In our study, the OR
associated with 3R/3R genotype was 1.43 (CI 0.94–2.16) for
LA versus PF and 1.10 (CI 0.68–1.78) for LA versus SA.
On the other hand, Ulrich et al. [22] found no marginal
eﬀect with any of these two polymorphisms but found a
signiﬁcant interaction of TS.2 with folate intake. Similarly,
the most recent studies [23, 24] found no marginal eﬀect
of either polymorphism but a slight interaction with folate
or vitamin B6 intake. The groups’ sizes in our study were
of the same order of magnitude as in the study of Chen
et al. [21], but the three other studies which did not show
any marginal eﬀect included larger groups (more than 500
individuals in each group). Given the size of our population,
we could a priori detect an OR of 1.7 with a power of at least
80%. It is highly probable that the TS gene, which produces
a key enzyme in folate metabolism, has an eﬀect only in
interaction with dietary exposures, which would explain why
this eﬀect was not found in our study. Moreover a new SNP
has been recently identiﬁed in the second repeat of the 3R
allele leading to split the allele 3R in 3RC and 3RG alleles as
a tri-allelic polymorphism. This variant could explain these
discrepant results since patients with 3RC/3RC genotype
haveatranscriptionalactivityofTScomparabletothosewith
2R/2R genotype [25].
In our study, the problem of multiple testing was
adequately controlled for each test performed by the
permutation procedure implemented in the combination
test. In the last analysis step, the tremendous number of
comparisons resulted in a drastic correction of each P-value,
which considerably lowered the testing power. Thus, our
negative results certainly do not deﬁnitively demonstrate
the absence of speciﬁc combination inﬂuencing colorectal
tumorigenesis, but more probably that, if it exists, this (of
these) eﬀect(s) is (are) low and could be found through8 Journal of Oncology
the initial (and further) genome-wide association studies of
colorectal cancer testing much larger numbers of patients
and controls [26, 27].
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